发明名称 |
Stratification of pancreatic and ovarian cancer patients for susceptibility to therapy with PTK2 inhibitors |
摘要 |
The present invention relates to a method for determining whether a cancer patient is susceptible to treatment with a protein tyrosine kinase 2 (PTK2) inhibitor, comprising detecting the expression of the E-cadherin protein in a cancer sample of said cancer patient, wherein an E-cadherin protein immunoreactivity score (IRS) of 0-2 indicates that the cancer patient is susceptible to treatment with a PTK2 inhibitor. Said detection of the expression of the E-cadherin protein in a cancer sample of a cancer patient is preferably conducted by way of an immunohistochemistry (IHC) method. Said IHC method preferably employs a primary antibody which is specific for E-cadherin and a secondary antibody which specifically reacts with the primary antibody. The present invention also relates to a method of treating a cancer patient whose cancer is characterized by an E-cadherin protein immunoreactivity score (IRS) of 0-2, comprising administering to the patient a therapeutically effective amount of a PTK2 inhibitor. In a further aspect, the present invention relates to a PTK2 inhibitor for use in the treatment of a cancer patient whose cancer is characterized by an E-cadherin protein immunoreactivity score (IRS) of 0-2. The present invention also provides a method of screening for a therapeutically effective PTK2 inhibitor comprising the steps of (a) providing cancer cells or a cancer cell line which are characterized by an E-cadherin protein immunoreactivity score of 2, 1, or 0 (1 being preferred and 0 being even more preferred); (b) contacting the cancer cell or the cancer cell line of (a) with a PTK2 inhibitor; and (c) evaluating whether the PTK2 inhibitor negatively affects the cancer cell/cancer cell lines. In a further aspect, the present invention relates to a method for stratifying cancer patients that are susceptible to treatment with a PTK2 inhibitor, comprising determining the E-cadherin IRS score in a cancer sample of said patient, wherein an E-cadherin protein immunoreactivity score (IRS) of 0-2 (i.e. 2, 1, or 0) indicates that the cancer patient is susceptible to treatment with a PTK2 inhibitor. The present invention also relates to a pharmaceutical package comprising a PTK2 inhibitor, and (a) instructions and/or an imprint indicating that said PTK2 inhibitor is to be used for the treatment of patients which suffer from a cancer which is characterized by an E-cadherin protein immunoreactivity score of 2, 1, or 0 (1 being preferred and 0 being more preferred); and/or (b) instructions and/or an imprint indicating that said patient is to be stratified by a method of the present invention; and/or (c) means to carry out a method as defined herein. |
申请公布号 |
US9274120(B2) |
申请公布日期 |
2016.03.01 |
申请号 |
US201414221370 |
申请日期 |
2014.03.21 |
申请人 |
Boehringer Ingelheim International GmbH |
发明人 |
Adolf Guenther;Garin-Chesa Pilar;Hirt Ulrich |
分类号 |
G01N33/53;C12Q1/00;G01N33/574;C12Q1/68 |
主分类号 |
G01N33/53 |
代理机构 |
|
代理人 |
Morris Michael P.;Stempel Alan R. |
主权项 |
1. A method of treating a carcinoma of the pancreas or ovarian cancer in a patient, said method comprising the following steps:
(a) determining whether said patient is susceptible to treatment with a protein tyrosine kinase 2 (PTK2) inhibitor by detecting the amount of expression of the E-cadherin protein in a cancer sample taken from said patient, wherein an E-cadherin protein immunoreactivity score (IRS) of 0 indicates that the patient is susceptible to treatment with a PTK2 inhibitor; and (b) treating said patient with a protein tyrosine kinase 2 (PTK2) inhibitor if it has been determined that said patient is susceptible to treatment with a protein tyrosine kinase 2 (PTK2) inhibitor. |
地址 |
Ingelheim am Rhein DE |